Mechanism of Action
Ghrelin Receptor Agonism
Activation of the growth hormone secretagogue receptor (GHSR-1a) — the ghrelin receptor — to drive GH release through a second pathway.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Compounds
2
Total studies
108
Human studies
29
FDA approved
0
Overview
Ghrelin receptor agonists activate GHSR-1a on pituitary somatotrophs and hypothalamic neurons. Unlike GHRH agonists, they work through a distinct signaling pathway and produce an additive effect when combined with GHRH analogs. Ghrelin receptor activation also stimulates appetite and may affect sleep architecture.
Ghrelin receptor agonism operates on a distinct pathway from GHRH-class peptides. GHSR-1a signals primarily through Gαq and phospholipase C rather than cAMP, enabling additive effects when co-administered with GHRH analogs. This is the pharmacological rationale for the common CJC-1295 + ipamorelin combination. Orally active non-peptide ghrelin mimetics (MK-677 / ibutamoren) have documented effects on sleep architecture, appetite, and IGF-1, but failed Phase 3 trials for Alzheimer's disease and frailty despite meaningful endocrine effects.
Receptor & signaling detail
GHSR-1a (growth hormone secretagogue receptor 1a) is a class A GPCR expressed on pituitary somatotrophs, hypothalamic arcuate and suprachiasmatic nuclei, and peripheral tissues. It signals through Gαq and displays constitutive activity — meaning inverse agonism is a theoretical therapeutic target.
How it works
- 1Binds to the ghrelin receptor (GHSR-1a), a class A GPCR.
- 2Activates Gαq → phospholipase C → IP3 / DAG → Ca²⁺ release.
- 3Amplifies GH release from pituitary somatotrophs.
- 4Synergizes with GHRH signaling when co-administered.
- 5Stimulates orexigenic neurons in the arcuate nucleus.
Downstream clinical effects
- Increased GH and IGF-1
- Improved sleep quality in some studies
- Increased appetite
- Potential improvements in body composition
Documented clinical implications
- GH and IGF-1 elevation within physiological range
- Increased REM and slow-wave sleep (MK-677)
- Appetite stimulation (can be therapeutic in cachexia)
- Modest lean mass gains in older adults (pilot trials)
Limitations & mechanism-driven side effects
- Increased appetite can drive weight gain
- Fluid retention and edema in some patients (MK-677)
- Insulin sensitivity modestly decreased (chronic GH elevation effect)
- Older GHRPs (hexarelin, GHRP-6) raised prolactin/cortisol; ipamorelin is selective
Discovery & development
Ghrelin itself was identified in 1999 as the endogenous ligand of the "orphan" GHS receptor discovered through GHRP pharmacology in the 1980s. MK-677 was developed by Merck and reached Phase 3 before discontinuation for the sought indications.
Peptides using this mechanism
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.
An oral ghrelin mimetic (not a peptide) that stimulates growth hormone release. Has extensive human data but has not achieved FDA approval.
Evidence status
MK-677 (ibutamoren) is oral and has Phase II data. Ipamorelin is a selective peptide ghrelin agonist with preclinical + pilot human data.
Frequently asked questions
Does ipamorelin cause appetite increase like MK-677?
Ipamorelin's short half-life (~2 hours) limits chronic orexigenic signaling. MK-677 has a half-life of ~24 hours and more persistent appetite effects.
Why combine CJC-1295 with ipamorelin?
GHRH agonism and ghrelin agonism act through different signaling pathways (Gαs vs Gαq). Co-administration produces additive or synergistic GH release versus either alone.
Is MK-677 a peptide?
No. MK-677 (ibutamoren) is a small-molecule non-peptide ghrelin receptor agonist. It is orally bioavailable unlike peptide ghrelin mimetics.
Does ghrelin agonism improve sleep?
MK-677 has documented increases in REM and stage 4 slow-wave sleep in controlled trials, particularly in older adults. Peptide ghrelin agonists have less direct sleep-architecture evidence.
Relevant best-of guides
Best Peptides for Muscle Recovery & Injury Healing
Peptides most studied for tissue repair, tendon healing, and post-exercise recovery — ranked by the quality of supporting research.
Best Peptides to Increase Growth Hormone Naturally
Growth hormone secretagogues ranked by pharmacological selectivity, duration of action, and regulatory status.
Best Peptides for Sleep Quality & Deep Sleep
Peptides with evidence for improving slow-wave sleep or sleep architecture — ranked by mechanism and data quality.
Best Peptides for Athletic Performance
Peptides associated with athletic performance contexts — ranked by evidence and WADA status.
Related articles
Peptides for Women: Safety, Benefits, and What’s Different
Deep Dive · 14 min
RFK Jr. Announces 14 Peptides Moving Back to Category 1: What It Means
Regulatory · 7 min
FDA Category 2 Peptide Ban: The Complete Guide
Regulatory · 7 min
Peptide Compounding in 2026: What Patients Need to Know
Guide · 5 min
Ipamorelin vs CJC-1295: GH Secretagogues Compared
Comparison · 10 min